Quell Therapeutics Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Quell Therapeutics Ltd. - overview
Established
2019
Location
London, England, UK
Primary Industry
Biotechnology
About
Based in London, UK, and founded in 2019, Quell Therapeutics Ltd. provides regulatory T cells (Treg) therapies as immunosuppression for patients recovering from a liver transplant. The company was co-founded by Giovanna Lombardi, Marc Martinez-Llordella, Alberto Sánchez-Fueyo, Hans Stauss, Emma Morris, and Elmar Jaeckel. In 2019 and 2021, Quell Therapeutics Ltd.
raised funding from Albion Capital and Syncona Limited. Quell Therapeutics Ltd. works with pharmaceutical companies, by offering the regulatory T cells (Treg) therapies for immune dysregulations, such as autoimmunity, inflammatory conditions, and solid organ transplantation, for patients recovering from a liver transplant. Therapies will enable patients to live with transplanted liver without taking immunosuppressive medication.
The company will offer the therapy under the research & preclinical development phase for future commercialization. The company generates revenue by selling the therapies for immunosuppression to pharmaceutical companies. Quell Therapeutics Ltd. ’s future strategy includes further research and preclinical development of immunosuppression therapies and expanding the senior leadership team.
Current Investors
Albion Capital, Syncona , SV Health Investors
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.quell-tx.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Quell Therapeutics Ltd. - timeline of key events
Quell Therapeutics Ltd. - financials
| Fiscal Year Ended | Mar 31, 2020 | Mar 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - |
| EBITDA (USD) | (5,405,021) | - | - | - | - |
| Operating Income (USD) | (5,521,625) | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - |
| NET Income (USD) | (4,847,856) | - | - | - | - |
| % Net Margin | - | - | - | - | - |
Quell Therapeutics Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.